Birchview Capital’s Protagonist Therapeutics PTGX Stock Holding History

Birchview Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.69M	Sell	35,000 -20,000	-36%	-$1.77M	2.1%	13
2025 Q4	$4.8M	Buy	55,000 +7,000	+15%	+$573K	2.81%	8
2025 Q3	$3.19M	Hold	48,000	–	–	2.41%	10
2025 Q2	$2.65M	Sell	48,000 -2	-0%	-$96	2.63%	9
2025 Q1	$2.32M	Buy	48,002 +2	+0%	+$84	2.02%	12
2024 Q4	$1.85M	Hold	48,000	–	–	1.51%	19
2024 Q3	$2.16M	Hold	48,000	–	–	1.87%	15
2024 Q2	$1.66M	Hold	48,000	–	–	1.54%	18
2024 Q1	$1.39M	Hold	48,000	–	–	1.13%	20
2023 Q4	$1.1M	Buy	48,000 +10,000	+26%	+$175K	0.86%	25
2023 Q3	$634K	Hold	38,000	–	–	0.54%	31
2023 Q2	$1.05M	Hold	38,000	–	–	0.79%	23
2023 Q1	$874K	Hold	38,000	–	–	0.68%	23
2022 Q4	$415K	Hold	38,000	–	–	0.29%	37
2022 Q3	$320K	Hold	38,000	–	–	0.23%	47
2022 Q2	$301K	Hold	38,000	–	–	0.22%	47
2022 Q1	$900K	Hold	38,000	–	–	0.65%	30
2021 Q4	$1.3M	Hold	38,000	–	–	0.84%	23
2021 Q3	$673K	Buy	38,000 +28,000	+280%	+$1.19M	0.46%	35
2021 Q2	$449K	Hold	10,000	–	–	0.27%	45
2021 Q1	$259K	Buy	+10,000	New	+$253K	0.15%	49

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Birchview Capital's PTGX Position: Q1 2026 in Review

Birchview Capital reduced its Protagonist Therapeutics (PTGX) stake by 36% in Q1 2026, selling an estimated $1.77M and leaving 35,000 shares worth $3.69M. The position accounts for 2.1% of the portfolio, ranked #13.

Birchview Capital first reported a position in PTGX in Q1 2021 and has held it in 21 quarters since. The position peaked at $4.8M in Q4 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

Birchview Capital held 35,000 shares of Protagonist Therapeutics worth $3.69M as of Q1 2026.
Birchview Capital sold 20,000 Protagonist Therapeutics shares in Q1 2026, an estimated $1.77M.
Protagonist Therapeutics made up 2.1% of Birchview Capital's portfolio in Q1 2026, its #13 holding.
Birchview Capital first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 21 quarters since.
Birchview Capital's Protagonist Therapeutics position peaked at $4.8M in Q4 2025.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.